—
C+
C+ The full Closelook — membership. Open the C+ overview

Ascendis Pharma AS (ASND) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Ascendis Pharma AS

ASND in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Ascendis Pharma builds drugs on its TransCon platform, which controls how a molecule releases in the body over time. It sells Skytrofa for children with growth hormone deficiency and Yorvipath for adults with chronic hypoparathyroidism. Its pipeline extends into other rare endocrine conditions and oncology. The company is based in Hellerup, Denmark, and lists in the United States.
Where it sits in the stack
Ascendis Pharma sits in our Healthcare sleeve, grouped with other Healthcare names listed in the United States; it plays no part in the AI build-out stack the diary tracks through our index.
Who it is priced against
Closelook's peer group places it with other scored Healthcare names domiciled and listed in the United States, including argenx, Regeneron and Vertex Pharmaceuticals; the market also compares it with Novo Nordisk on the endocrine side.
Why Closelook tracks it
It carries a Closelook score, with momentum the strongest of its modules and valuation the weakest. It holds no seat in our index and has drawn no quotes in the diary so far.
What the diary watches
Whether the endocrinology pipeline delivers further approvals and how the gap between its share price and the trimmed analyst target closes or widens.

Ascendis Pharma AS (ASND) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 52/100 composite (momentum 55, quality 63, valuation 27) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ASND, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 7 analyst actions on the wire · latest: price target by Oppenheimer, 2026-09-01

The Street on this name

Analyst actions and the latest print for ASND from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Oppenheimer — target 312 Target set to $312 (+19.9% to spot) 2026-09-01
  • Price target Morgan Stanley — target 273 from 275 Target cut to $273 from $275 (+3.8% to spot) 2026-09-01
  • Price target Jefferies — target 330 from 333 Target cut to $330 from $333 (+24.4% to spot) 2026-08-31

7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ASND on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months · buybacks 17 m USD in FY2025

Dividends and capital return

What ASND pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 17 m USD 0.1% of today's market value
  • Share count +4.7% in FY2025 116 m USD of stock-based compensation in the year
  • Capital returned 17 m USD · 38% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 63/100 · S&P 500 fund at 63, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-21
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +6.7% over 20 sessions. Factor regime → 2026-09-21
  • Sector × region Health care in US: +1.1% week · −1.6% month · +13.1% quarter · +11.2% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-21
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-22

Quick answers

What is Ascendis Pharma AS (ASND)?

Ascendis Pharma AS trades as ASND on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-22.

Is ASND in a Closelook index?

Not currently — Ascendis Pharma AS is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-22.

What is Ascendis Pharma AS's Closelook composite score?

52 out of 100, with momentum 55, quality 63 and valuation 27 sub-scores, as of 2026-09-22. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ASND trade against its moving averages?

Pullback inside an uptrend stack: Trades -6.5% vs the 50-day and +1.3% vs the 200-day average, 15.8% below the 52-week high and +27.7% off the 52-week low. Computed from daily closes. As of 2026-09-21 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Ascendis Pharma AS do?

Ascendis Pharma builds drugs on its TransCon platform, which controls how a molecule releases in the body over time. It sells Skytrofa for children with growth hormone deficiency and Yorvipath for adults with chronic hypoparathyroidism. Its pipeline extends into other rare endocrine conditions and oncology. Closelook's peer group places it with other scored Healthcare names domiciled and listed in the United States, including argenx, Regeneron and Vertex Pharmaceuticals; the market also compares it with Novo Nordisk on the endocrine side.

Where does Ascendis Pharma AS sit in the AI build-out?

Ascendis Pharma sits in our Healthcare sleeve, grouped with other Healthcare names listed in the United States; it plays no part in the AI build-out stack the diary tracks through our index. It carries a Closelook score, with momentum the strongest of its modules and valuation the weakest. It holds no seat in our index and has drawn no quotes in the diary so far.

Does Ascendis Pharma AS pay a dividend?

No cash distribution shows in Ascendis Pharma AS’s price series over the last three years. In fiscal 2025 the company bought back 17 m USD of its own shares, 38% of that year’s free cash flow. The share count rose 4.7% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Ascendis Pharma AS recently?

The most recent analyst action on Ascendis Pharma AS on the Closelook wire is a price target by Oppenheimer on 2026-09-01 (target 312). 7 actions on the analyst wire since 2026-08-13: 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ASND, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.